This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brueckner, R. P.
Right arrow Articles by Schuster, B. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brueckner, R. P.
Right arrow Articles by Schuster, B. G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 1998, p. 1293-1294, Vol. 42, No. 5
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Prophylaxis of Plasmodium falciparum Infection in a Human Challenge Model with WR 238605, a New 8-Aminoquinoline Antimalarial

Ralf P. Brueckner,1,* Trinka Coster,2 David L. Wesche,1,dagger Moshe Shmuklarsky,3 and Brian G. Schuster1

Division of Experimental Therapeutics1 and Division of Communicable Diseases and Immunology,3 Walter Reed Army Institute of Research, Washington, D.C. 20307-5100, and Clinical Studies Branch, U.S. Army Medical Research Institute of Infectious Disease, Ft. Detrick, Frederick, Maryland 21702-50112

Received 25 November 1997/Returned for modification 17 February 1998/Accepted 10 March 1998

The prophylactic efficacy of WR 238605, a primaquine analog, was studied with a human Plasmodium falciparum challenge model. A single oral dose of 600 mg, administered 1 day prior to challenge, successfully protected three of four subjects. The fourth subject developed mild, oligosymptomatic malaria on day 31, with drug concentrations one-half of those in the protected individuals. WR 238605 appears to be a promising prophylactic drug for P. falciparum malaria.

* Corresponding author. Mailing address: Department of Pharmacology, Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Washington, DC 20307-5100. Phone: (301) 295-7802 or (301) 295-7784. Fax: (301) 295-7755. E-mail: LTC_Ralf_Brueckner{at}WRSMTP-ccMail.Army.Mil.

dagger Present address: Ann Arbor, MI 48105.

Antimicrobial Agents and Chemotherapy, May 1998, p. 1293-1294, Vol. 42, No. 5
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • PONSA, N., SATTABONGKOT, J., KITTAYAPONG, P., EIKARAT, N., COLEMAN, R. E. (2003). TRANSMISSION-BLOCKING ACTIVITY OF TAFENOQUINE (WR-238605) AND ARTELINIC ACID AGAINST NATURALLY CIRCULATING STRAINS OF PLASMODIUM VIVAX IN THAILAND. Am J Trop Med Hyg 69: 542-547 [Abstract] [Full Text]  
  • Ball, M. D., Bartlett, M. S., Shaw, M., Smith, J. W., Nasr, M., Meshnick, S. R. (2001). Activities and Conformational Fitting of 1,4-Naphthoquinone Derivatives and Other Cyclic 1,4-Diones Tested In Vitro against Pneumocystis carinii. Antimicrob. Agents Chemother. 45: 1473-1479 [Abstract] [Full Text]  
  • Vennerstrom, J. L., Nuzum, E. O., Miller, R. E., Dorn, A., Gerena, L., Dande, P. A., Ellis, W. Y., Ridley, R. G., Milhous, W. K. (1999). 8-Aminoquinolines Active against Blood Stage Plasmodium falciparum In Vitro Inhibit Hematin Polymerization. Antimicrob. Agents Chemother. 43: 598-602 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»